EMILY SARRIS KELBERT PA-C NPI 1104482066

NPI Details

Emily Sarris Kelbert, PA-C is a physician assistant in Jacksonville, FL with 8 years of experience. The provider is a physician assistant is a person who has successfully completed an accredited education program for physician assistant, is licensed by the state and is practicing within the scope of that license. Physician assistants are formally trained to perform many of the routine, time-consuming tasks a physician can do. In some states, they may prescribe medications. They take medical histories, perform physical exams, order lab tests and x-rays, and give inoculations. Most states require that they work under the supervision of a physician. Emily Sarris Kelbert, PA-C NPI is 1104482066. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

4500 SAN PABLO RD S
JACKSONVILLE, FL
ZIP 32224-865
Phone: (904) 953-2000

The NPI 1104482066 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, belatacept, 1 mg (HCPCS:J0485)
• Injection, vedolizumab, 1 mg (HCPCS:J3380)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, tocilizumab, 1 mg (HCPCS:J3262)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, remdesivir, 1 mg (HCPCS:J0248)
• Injection, eptinezumab-jjmr, 1 mg (HCPCS:J3032)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, infliximab-axxq, biosimilar, (avsola), 10 mg (HCPCS:Q5121)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, ceftriaxone sodium, per 250 mg (HCPCS:J0696)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Transfusion of blood or blood products (HCPCS:36430)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Collection of blood sample from implanted device (HCPCS:36591)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, ertapenem sodium, 500 mg (HCPCS:J1335)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Infusion, albumin (human), 25%, 50 ml (HCPCS:P9047)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Collection of blood sample from central venous tube (HCPCS:36592)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Drawing of blood for a medical problem (HCPCS:99195)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Intravenous injection, bebtelovimab, includes injection and post administration monitoring (HCPCS:M0222)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Declotting of central venous tube (HCPCS:36593)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)

The enumeration date for this NPI number is 5/16/2019 and was last updated on 2/7/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: